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Implantable hyaluronic acid-deferoxamine conjugate prevents
nonunions through stimulation of neovascularization
Alexis Donneys 1, Qiuhong Yang2, Marcus Laird Forrest2, Noah S. Nelson1, Ti Zhang2, Russell Ettinger1, Kavitha Ranganathan1,
Alicia Snider1, Sagar S. Deshpande1, Mark S. Cohen3 and Steven R. Buchman1
Approximately 6.3 million fractures occur in the U.S. annually, with 5–10% resulting in debilitating nonunions. A major limitation to
achieving successful bony union is impaired neovascularization. To augment fracture healing, we designed an implantable drug
delivery technology containing the angiogenic stimulant, deferoxamine (DFO). DFO activates new blood vessel formation through
iron chelation and upregulation of the HIF-1α pathway. However, due to its short half-life and rapid clearance, maintaining DFO at
the callus site during peak fracture angiogenesis has remained challenging. To overcome these limitations, we composed an
implantable formulation of DFO conjugated to hyaluronic acid (HA). This compound immobilizes DFO within the fracture callus
throughout the angiogenic window, making it a high-capacity iron sponge that amplifies blood vessel formation and prevents
nonunions. We investigated implanted HA-DFO’s capacity to facilitate fracture healing in the irradiated rat mandible, a model
whereby nonunions routinely develop secondary to obliteration of vascularity. HA-DFO implantation significantly improved
radiomorphometrics and metrics of biomechanical strength. In addition, HA-DFO treated mandibles exhibited a remarkable 91%
bone union rate, representing a 3.5-fold improvement over non-treated/irradiated controls (20% bone union rate). Collectively, our
work proposes a unique methodology for the targeted delivery of DFO to fracture sites in order to facilitate neovascularization. If
these findings are successfully translated into clinical practice, millions of patients will benefit from the prevention of nonunions.
npj Regenerative Medicine            (2019) 4:11 ; https://doi.org/10.1038/s41536-019-0072-9
INTRODUCTION
Delayed unions and nonunions are among the most debilitating
fracture pathologies affecting approximately 250,000–500,000
patients per year.1–6 Angiogenesis and osteogenesis are intimately
coupled, and impaired angiogenesis is often a predisposing factor
underlying failed fracture healing. Vital temporal considerations
exist in the relationship between nonunion development and
angiogenesis. The first two weeks after fracture represent a critical
window in the angiogenic-osteogenic coupling process whereby
the effects of impaired neovascularization are intensified, poten-
tially leading to nonunion.7–15 Conversely, this temporal niche
may also represent a window of opportunity for targeting
impaired angiogenesis therapeutically in order to prevent
nonunions.
Emerging pre-clinical studies demonstrate utility in promoting
angiogenesis during bone regeneration and healing utilizing
therapeutic strategies. Perhaps the most promising is the use of
deferoxamine (DFO) for these motives. DFO is a naturally
occurring siderophore produced by Streptomyces pilosus, already
FDA-approved for the treatment of transfusional iron-overload.16
Investigators have found an alternate utility for DFO as a potent
prolyl-hydroxylase inhibitor (PHDi) and angiogenic stimulant. DFO
triggers angiogenesis by chelating iron at the callus site and
subsequently inhibiting the prolyl-hydroxylation of HIF-1α. In turn,
this favors accumulation of HIF-1α, leads to nuclear translocation,
dimerization with HIF-1ß, and transactivation of VEGF and other
downstream mediators of new blood vessel formation.17–20
Utilizing this mechanism, DFO has been shown to augment
angiogenesis in vitro and to augment callus neovascularization
when serially injected into fracture sites in animal models,
resulting in improved osteogenesis.21–25
Our laboratory has subsequently extended the use of this
powerful strategy to improve pathologic fracture healing in a
rodent model whereby the vascular microarchitecture has been
altered and obliterated by radiotherapy, resulting in a high
number of nonunions. The addition of serially injected DFO in
these fractures elicited remediations in metrics of vascularity,
osteocyte viability, callus mineralization and biomechanical
strength. Moreover, these remediations facilitated a 2.35-fold
improvement in bone union over non-treated/irradiated controls,
in a model where nonunions are the expected outcome.26–29
Although these results are promising, the current method of
DFO delivery in pre-clinical studies is impractical for human
application and may impede its clinical translation. Due to its short
plasma half-life, small size, rapid clearance and viscosity profile,
multiple localized injections of DFO must be administered over a
prolonged time-period, and accurate dosing is precluded by
fracture site effusion. Furthermore, repeated injections introduce
pain and inflammation, and increase the potential for infection at
the healing interface.
To remove the need for repeated injections, we developed an
implantable formulation to be introduced into the fracture site at
the time of surgical repair. We controlled the timing of drug
release by coupling DFO to a low molecular weight hyaluronic
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acid (HA) cross-linked scaffold, which provides structural support.
HA is a linear hydrophilic polysaccharide, naturally occurring in the
extracellular matrix of animal tissues.30 The HA carrier was selected
based on its biocompatibility, biodegradability, and modifiable
viscoelastic properties, which make it an attractive tissue filler
device and vehicle for sustained drug delivery. While other
researchers have reported modifications such as the use of
liposomal formulations, dextrans and transdermal delivery sys-
tems to extend DFO release, HA exhibits additional features that
make it more suitable in the setting of bone healing.31–34 HA has
demonstrated intrinsic osteogenic capacity and anti-inflammatory
properties that improve wound healing by minimizing tissue
destruction secondary to inflammation.35–38 Additionally, HA has
been FDA approved for decades as an injectable filler device,
therefore its clinical utility and limited side-effect profile are
well known.
Our sustained release kinetics were designed to facilitate DFO
delivery over a 2–4-week period after implantation to ensure that
the DFO was active before, during and after peak fracture
angiogenesis which occurs approximately 7–14 days after bone
injury. In addition, modifications in HA-DFO crosslinking were
explored utilizing UV photo-crosslinking methacrylate chemistry.
This enabled further extension in the retention time of the
molecule.
The viscoelastic characteristics of HA-DFO facilitated localized
implantation, maintained the drug at the fracture site for
sustained release dosing of DFO over weeks, and eliminated the
potential for fracture site effusion. Employing this technology in
our established model of radiotherapy-induced non-unions, we
investigated the therapeutic potential of HA-DFO to remediate
obliterated vascularity and promote osteogenesis in the aftermath
of radiation injury. Collectively, this work highlights a therapeutic
strategy that may be readily translatable to offer a transformative
solution for the management of clinical nonunions.
RESULTS
Development of implantable HA-DFO
The general chemical structure of HA-DFO is depicted in (Fig. 1a).
Various implantable formulations of HA-DFO differing in metha-
crylated crosslinking (See Figs 1b–d), or HA molar mass and DFO
concentration (See Fig. 2) were synthesized and tested. These
formulations were investigated utilizing (1) NMR spectroscopy, (2)
spectrophotometric DFO quantification, (3) iron binding capacity,
(4) enzymatic degradation, and (5) pharmacokinetic testing. The
results of these five investigations are detailed as follows:
NMR spectroscopy demonstrated that the primary amine group
of DFO was covalently conjugated to the unoccupied carboxylic
acid groups of the HA-DFO backbone, and the successful
conjugation was confirmed by the presence of characteristic
peaks of Methacrylic anhydride (MA), DFO and HA in their 1H-NMR
spectra (Fig. 1b). The degree of molar substitution was calculated
to be approximately 64%, and the degree of weight substitution
of the DFO to HA backbones was found to be 15.95%, indicating
that nearly 90% of the conjugated DFO was maintained during the
processes of reaction and purification.
Spectrophotometric quantification of DFO in the HA-DFO-MA
conjugate demonstrated that 215–752 kDa conjugates retained
85–95% of the unmodified DFO’s binding capacity for Fe (III).
When exposed to a UV source at 365 nm for 20 min in a 96-well
plate, the clear solution turned into a clear and homogenous gel.
To observe iron binding capacity, HA (752 kDa)-DFO-MA was
incubated with the FeCl3 solution overnight. The color of the
hydrogel became orange-red, indicating formation of the Iron (III)-
chelator complex (Fig. 1c).
To measure enzymatic degradation, the effects of hyaluroni-
dase on the molecular weight of unmodified HA (752 kDa), and its
two derivatives, HA (215 kDa)-DFO and HA (752 kDa)-DFO-MA
were observed. The results are shown in Fig. 1d. The molecular
weights decreased within 1 h to less than 5% of their initial
molecular weights and to approximately 2% as the incubation
proceeded. These results suggested that chemical modification of
the HA on its carboxylic acid groups did not affect the
hyaluronidase driven enzymatic degradation in simulated phy-
siological environments.
The release profiles of free DFO and HA-DFO conjugates were
evaluated in physiologic PBS solution at 37 °C. Release kinetics
were fitted using a first-order model. As expected, free DFO
exhibited a short half-life (t1⁄2= 0.5 h). By comparison, both
conjugates (HA-215kDa-DFO and HA-752kDa-DFO) demonstrated
a sustained release pattern with 50% of the DFO being retained at
10 days (Fig. 2).
Ultimately, HA (752 kDa)-DFO (13% wt/wt) was selected for
in vitro HUVEC applications and in vivo implantation in animal
studies. The HA-752kDA-DFO formulation was chosen due to
the similarity between release kinetics of the two formulations,
as well as the fact that this formulation minimized reported
concerns regarding DFO-induced cytotoxicity at high
concentrations.39
In vitro investigation of HA-DFO in irradiated HUVECs
Live cell imaging was performed in vitro to assess tubule
formation as a proxy for angiogenesis. Based on our prior
reported results, radiation significantly hampers tubule formation
and leads to aggregation, clumping, and an inability of cellular
organization, whereas injected DFO (iDFO) administration remedi-
ates these effects, leading to near normal tubule formation.26,27
Here, we examine the effects of HA-DFO in comparison to iDFO.
Three groups of irradiated Human Umbilical Vein Endothelial Cells
(HUVECs) were examined as follows: 50 µM iDFO, 50 µM HA-DFO,
100 µM HA-DFO. The experiment was conducted in triplicate.
ANOVA was performed for group comparisons, and all compar-
isons were performed within the respective timepoint. p < 0.05
was considered statistically significant. We observed a significant
increase between 50 µM iDFO and 100 µM HA-DFO at 4 h of
incubation (p= 0.033) and trending increases between 50 µM
iDFO and 100 µM HA-DFO at 2 and 3 h (p= 0.055 and 0.066),
indicating superiority in tubule formation with 100 µM HA-DFO.
Within 2 h of incubation, live cell imaging demonstrated more
observable organization and more robust vascular networks with
100 µM HA-DFO when compared to other experimental groups.
Though no statistical differences were observed between 50 µM
HA-DFO and 100 µM HA-DFO at 2 and 3 h, the overall observed
trend, in concurrence with a significant difference at 4 h, implied a
dose-response relationship (Figs 3a, b). See Supplemental Material
Movie S1 for recorded imaging.
In vivo HA-DFO investigation in the irradiated non-union rat
model
Forty-four male Sprague Dawley rats underwent mandibular
osteotomy and fixator placement immediately posterior to the
third molar. Experimental animals received radiation (XRT)
preoperatively, and received either no treatment, iDFO injection
series postoperatively, or HA-DFO implantation intraoperatively.
All animals underwent µCT analysis, biomechanical testing and
bony union assessment (Fig. 4a).
Micro-CT (µCT) imaging demonstrated decreases in radio-
morphometrics for the radiation group (XFx) that were remediated
with the addition of both iDFO and HA-DFO therapies. For metrics
of BMD, TMD and BVF, there was no difference between the two
treatments, and both treatments improved upon XFx (Figs 4b, c).
Biomechanical observations paralleled µCT findings. We observed
decreases in Stress and Failure Load metrics for the radiation
group that were restored with the addition of both iDFO and
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HA-DFO therapies. There was no difference in Stress and Failure
Load between the two treatments, and both treatments were
superior to XFx (Fig. 4d).
Bony union results demonstrated that non-irradiated fractures
(Fx) reproducibly formed bony unions in 100% of cases, whereas
only 20% of irradiated fractures (XFx) went on to achieve bony
union. iDFO administration improved bony union to 67%, which
represented an increase of 47-percentage points over XFx.
Remarkably, we observed a 91% union rate in the HA-DFO group,
representing an increase of 71-percentage points over XFx, and a
24-percentage point gain over standard iDFO (Table 1).
DISCUSSION
Delayed unions and nonunions are commonly caused by
conditions such as underlying vascular disease resulting from
diabetes, advanced age or uremia; pathologic states that directly
weaken bone such as osteoporosis; anatomic predispositions to
avascular necrosis; or iatrogenic causes associated with cancer
management such as chemotherapy or radiotherapy. These
conditions share a mechanistic commonality in that each impairs
neovascularization during the fracture repair process.7 Here, we
detail the composition of a novel implantable angiogenic/































Fig. 1 Development of implantable HA-DFO. a HA-DFO general chemical structure. b 1H-NMR spectra (D2O, 400 MHz) of HA (752 kDa)-DFO-
MA and HA (752 kDa)-DFO confirming the characteristic peaks of MA (6.5–5.5 ppm), HA (4.0–3.0 ppm) and DFO (2.0–1.0 ppm), highlighted
from left to right, respectively. The peak at δ= 4.70 in each spectrum corresponds to the solvent residue. c HA (752 kDa)-DFO-MA hydrogel
before and after overnight incubation with iron. Note the rust color indicating successful iron chelation within the Hydrogel-Iron (III) complex.
Scale bar length= 5mm. d Percent molecular weight of unmodified HA (752 kDa), and its two derivatives in response to hyaluronidase
enzymatic degradation
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facilitation of fracture healing in an irradiated nonunion animal
model. In vitro, results indicate that these effects are due to
activation of angiogenesis, despite prior radiation-dependent
inhibition of blood vessel formation. In vivo, our results suggest
that implantable HA-DFO may be superior to iDFO in preventing
nonunions.
The concept of augmenting vascularity to promote bone
regeneration and healing has distinctive clinical origins dating
back to the development of distraction osteogenesis. Gavriil
Ilizarov discovered that mechanical tension introduced across a
fracture site led to augmented vascularity and circulation above
and beyond what would be expected during normal fracture
healing. Reportedly, this hypervascular response treated osteo-
myelitis and nonunions at a time when antibiotics were not readily
available.40 Since then, our knowledge and understanding of the
angiogenic-osteogenic interface, and the timing of fracture callus
vascularization, has increased considerably owing to the devel-
opment of cellular, molecular and genetic methodologies. This
increased understanding has created a renaissance of experi-
mentation focused on identifying and implementing alternative
triggers of angiogenesis to improve osteogenesis—as opposed to
the mechanical stimulation techniques fostered by Ilizarov. The
agents used in these studies vary, including the direct delivery of
angiogenic growth factors, such as VEGF, FGF and TGF; regulation
of angiogenesis inhibition with thrombospondin-2 modulation;
less invasive mechanical stimulants such as ultrasound and
alterations in weight bearing; and up-regulation of the HIF-1α
pathway with DFO, L-mimosine and dimethyloxalylglycine.7,41
While non-angiogenic therapeutics such as recombinant human
BMP-2 and 7, and Teriparatide have succeeded in translation, they
have achieved only marginal clinical efficacy as osteogenic
therapeutics due to associated complications and side effect
profiles. Thus far, therapeutic angiogenic stimulants intended for
enabling or accelerating osteogenesis have not yet reached
clinical application.
With regards to the potential clinical translation of angiogenic
stimulants, mediators of the HIF-1α pathway have offered the
most persuasive evidence of clinical proximity and osteogenic
efficacy. While the direct administration of VEGF is efficacious in
preclinical models, the need for recombinant protein and/or
genetic delivery approaches raise concerns that this technique is
not yet ready for clinical adoption. This avenue is further
encumbered by the high cost of producing such therapies.22 As
such, Prolyl hydroxylase inhibitors, such as DFO, have emerged as
a more attractive approach for promoting osteogenesis by
indirectly stimulating angiogenesis through upregulation of the
HIF-1α pathway. Wan and Shen et al. eloquently demonstrated the
ability of DFO to accelerate bone regeneration during distraction
osteogenesis, and femur fracture healing in murine models,
respectively.23,24 Our laboratory subsequently investigated the
ability of DFO to restore angiogenesis and fracture healing in a
more rigorous animal model of irradiated nonunions, whereby the
vascular microarchitecture was obliterated by a human-equivalent
dose of radiotherapy. Collectively, we saw an improvement in the
prevention of non-unions by 45 percentage points over non-
Fig. 2 Release kinetics of free DFO and HA-DFO conjugates. In vitro
testing of the three compounds in PBS at 37 °C (n= 3, Mean ± SD is
shown). Note the rapid clearance of free DFO (t1/2~0.5 h) in
comparison to the sustained release patterns exhibited by both
HA-DFO conjugates (t1/2~10 d)
Fig. 3 HA-DFO stimulates angiogenesis in vitro in HUVEC cells
exposed to radiation. a Three groups of irradiated HUVECs
demonstrate variable tubule formation in response to deferoxamine
despite radiation injury. Scale bar length= 200 µm. Qualitatively,
note the visibly increased tubule density and organization in the
100 µM HA-DFO sample when compared to 50 µM iDFO and 50 µM
HA-DFO, even at only two hours of incubation (See Supplemental
Material Movie S1 for recorded imaging). b Quantitatively, we
observed a significant difference between 100 µM HA-DFO and both
50 µM doses of iDFO and HA-DFO at the 4-h time mark. Mean
tubules per high power field are represented as group means and
error bars indicate standard deviation. ANOVA was performed for
group comparisons. All comparisons were performed within the
respective timepoint. * indicates p < 0.05
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treated controls in a model where nonunions are the expected
outcome.27,28
Based on this work, the first in-human application of DFO to
facilitate osteogenesis in previously irradiated bone was realized.
In a collaboration between our laboratory, and reconstructive
surgeons at Stanford University, the clinical repurposing, volu-
metric dosing and delivery of DFO to facilitate distraction
osteogenesis in a young adult patient with maxillary hypoplasia
secondary to previous radiotherapy was achieved.42 The clinical
utility of distraction osteogenesis in patients exposed to radiation
is currently eschewed due to the prohibitive incidence of
nonunions. Nonunion in this setting is thought to result from
the paucity of vascular ingrowth provided by irradiated tissues
and the unmet high angiogenic metabolic demands incurred by
mechanical bone regeneration. In this unique case, the patient
underwent trans-cutaneous catheter placement to the right and
left pterygo-maxillary regenerative sites to enable delivery of DFO
prior to distraction. Our dosing was calculated volumetrically,
based on the anticipated 3-D area of bone regeneration, and our
experience afforded by our pre-clinical dosing of injectable DFO.
Accidental dislodgement of the left catheter prior to distraction
resulted in exclusive delivery of DFO to the right regenerate area,
establishing the patient as his own control. We observed an
increased bone area and radiodensity in the treated areas
indicating accelerated bone regeneration due to the successful
delivery of DFO at 3-months of consolidation (~25 and 30%,
respectively). This case report demonstrates the clinical utility of
this highly effective angiogenic/osteogenic therapeutic and
demonstrates proof of concept for human application. Despite
this promising result, this report also highlights the current
cumbersome delivery methodologies, and timely need for more
practical, implantable options for this efficacious therapy in order
to facilitate its transfer from the bench to the bedside. A five-
injection series, or catheter-based delivery system may be viewed
as an undesirable last-resort option by patients, rather than a new
standard of care. Although these cumbersome delivery methods
ensure drug delivery into the osteogenic site, they would require
frequent office visits or longer inpatient stays, both of which
would carry substantial expenses and introduce the potential for
human error. In addition, repeated injections or transcutaneous
catheter delivery also expose the bony regenerate to skin flora,
potentiating the risk of infection and failure of the reconstruction.
Taken together, these numerous barriers make a fully-implantable
DFO-construction an exceedingly attractive alternative.
Given these challenges, we have developed a novel HA-DFO
conjugate to deliver DFO gradually to a fracture site over the
length of the critical period of angiogenesis that is needed for new
bone development. HA was first approved as a device in the 1960s
and has since been applied as a filler cosmetically and for other
structural injections or implantations in the body. It has gained
popularity as a drug delivery agent only recently and has been
shown to enhance locoregional drug retention along with
Fig. 4 In vivo: HA-DFO restores mineralization and enhances
biomechanical strength in irradiated fracture healing. a In vivo
experimental timeline, normal peak fracture angiogenesis timing
and schematic of the rat mandible depicting drug delivery methods
and release kinetics. b Representative µCT images by treatment
group. Notice the decreased bony bridging across the fracture site
in the XFx sample that is restored in both iDFO and HA-DFO treated
mandibles. c Radiomorphometrics: BMD, TMD, BVF, and (d)
Biomechanical metrics: S and FL. ANOVA was performed for group
comparisons. Group means are shown, and error bars indicate
standard deviation. * indicates p < 0.05
Table 1. Bony Union rates by treatment group
Fx XFx iDFO HA-DFO
100% 20% 67% 91%
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substrate delivery of agents conjugated to its crosslinked back-
bone. This delivery platform can release a conjugated drug locally
in soft tissue or deep tissue locations over a period of days to
weeks depending on the avidity of the conjugation link or the
degree of the HA polymer crosslinking.
The sustained release delivery of DFO through conjugation with
HA allows for better drug-fracture interface during the critical
angiogenic period of healing, allowing for superior union
formation over pulsed DFO injections, without overgrowth of
bone or biomechanical inferiority to normal fracture callus, even in
the setting of high dose radiation damage. Another significant
benefit of this technology is related to the kinetics of the HA-DFO
release reaction, which limits free DFO concentrations to a fraction
of what would be experienced through systemic delivery or
repeated local injections of free DFO. The blood serum
concentration of free DFO observed with HA delivery is therefore
several orders of magnitude lower than the FDA-approved doses
given for iron-overload treatments. Lastly, it is important to note
that we did not expect improved bone union with HA-DFO,
beyond what was observed with pulsed DFO injections. Rather,
our intent was to investigate efficacy. While the iron chelating
properties and angiogenic mechanisms of HA-DFO were con-
firmed in our in vitro studies, these new findings raise inquiries
regarding the contribution of HA alone to the angiogenic and
osteogenic mechanisms during irradiated fracture healing that will
require further dedicated investigation. Taken together, these
remarkable observations support the impact and potential of HA-
DFO for preventing or treating delayed unions or nonunions.
Advancement of this platform clinically could address a critical
gap in the management of these challenging bone pathologies for
patients who lack effective reconstructive options.
METHODS
Hyaluronan sodium salts (752 kDa) were purchased from Lifecore
Biomedical, Inc. (Chaska, MN). Hyaluronic Acid (752 kDa)-Deferoxamine
conjugate synthesized in house. Methacrylic anhydride, 2-Hydroxy-4′-(2-
hydroxyethoxy)-2-methylpropiophenone (irgacure® 2959) and hyaluroni-
dase from bovine testes (EC 3.2.1.35, 750–3000 U/mg) were purchased
from Sigma Aldrich (St. Louis, MO). Sodium hydroxide was purchased from
J.T. Baker (Center Valley, PA). Iron (III) chloride (anhydrous, 98%) was
obtained from Alfa Aesar (Ward Hill, MA). Thermo Scientific™ SnakeSkin™
Dialysis Tubing (10 K MWCO) and organic solvents of analytical grade were
obtained from Fisher Scientific (Lenexa, KS). Double distilled water (ddH2O)
was used in syntheses, characterization and cell-culture (sterilized by
autoclaving).
Preparation of implantable HA-DFO conjugates
HA-DFO is produced by conjugating HA (0.2–1MDa) and DFO (10–15% w/w)
utilizing [1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide] (EDC). EDC is a
zero-length crosslinking agent used to couple carboxyl or phosphate groups
to primary amines. The chemical modification of HA can be performed
utilizing this method to conjugate DFO at its carboxyl region and forms a
prodrug that is later cleaved at its target site. Methacrylated HA-DFO (HA-
DFO-MA) was synthesized in order to facilitate crosslinking and further
modify the degradation profile. MA was first attached to the carboxylic acid
groups of the HA-DFO (752 kDa)-DFO conjugate following a procedure
reported elsewhere with some modifications.43 Briefly, approximately 100mg
of the HA-DFO (17.8%, w/w) was dissolved in 7-mL ddH2O and then one
molar equivalent of methacrylic anhydride was added in the solution with
gentle stirring. The pH of the mixture was kept at 8 using a 2.5-N sodium
hydride. The reaction was carried out at room temperature for 2 h, followed
by storing at 2–8 °C overnight. Afterwards, the mixture was transferred into
the dialysis tubing and dialyzed against ddH2O for 3 days. The dry form of
the HA-DFO-MA was obtained via lyophilization. A stock solution of 10% w/v
of Irgacure 2959 was freshly prepared in an ethanol-acetone mixture (70/30;
v/v). Two microliters of Irgacure 2959 was added into 1mL of HA-DFO-MA
(10mg/mL) in ddH2O at a concentration of 10-mg/mL, and the mixture was
gently vortexed for 30 s. Approximately a 100-μL aliquot was transferred into
the 96-well cell culture plate, which was subsequently exposed to UV lamp at
a wavelength of 365 nm for 20 minutes.
1H Nuclear magnetic resonance (NMR) spectroscopy
The HA (752 kDa)-DFO or HA (752 kDa)-DFO-MA was dissolved in
deuterium oxide (D2O) and their
1H NMR spectra were collected on a
Bruker Avance 400 MHz NMR Spectrometer (Bruker Corporation, MA, USA).
Spectrophotometric DFO quantification
The quantification of DFO in the HA-DFO-MA conjugate was determined
spectrophotometrically by converting the methacrylated HA-DFO to the
iron-saturated ferrioxamine using a modified method.44 Three mM of iron
(III) chloride (FeCl3) was incubated with a series of standard solutions of
DFO (0.05–0.5 mg/mL), 1-mg/mL HA (215 kDa or 752 kDa)-DFO-MA at
ambient temperature overnight, followed by recording the absorption at
430 nm using a UV microplate reader (SpectraMax Gemini; Molecular
Devices, Sunnyvale, CA). The amount of DFO in the formulation was
determined by quantitating respective HA-DFO-MA generated ferrioxa-
mine species with the calibration curve of the ferrioxamine standard
solutions prepared from unmodified DFO.
Iron binding capacity
Approximately 100 μL of HA (752 kDa)-DFO-MA was incubated with 500 μL
3-mM FeSO4 in a 1.5-mL Eppendorf tube, and the mixture was shaken
overnight on an orbital shaker at 50 rpm overnight. The preparation was
photographed before and after iron incubation to observe oxidation.
Enzymatic degradation
The kinetics of enzymatic degradation of HA was studied by monitoring
the molecular weight change. First, 1 mg/mL of unmodified HA (752 kDa),
HA (752 kDa)-DFO or methacrylated HA (752 kDa)-DFO solutions was
prepared in 4mL of PBS (10mM, pH7.4), and then hyaluronidase solution
(10 μg/mL) was added into the reaction system. While the mixture was
incubated at 37 °C, the molecular weights of 100-μL aliquots of the
samples were monitored by gel-permeation chromatography (GPC) at
25 °C on a Shimadzu 2010CHT with a refractive index detector (RID-10A,
Shimadzu Scientific Instruments, KS), using a Shodex OHpak SB-806 HQ
column (Showa Denko America, Inc., New York, NY) with 5-mM ammonium
acetate as the mobile phase at a flow rate of 0.8 mL/min.
In vitro release kinetic testing
Free DFO, HA (215 kDa)-DFO and HA (752 kDa)-DFO conjugates were added
to 4mL of PBS (pH 7.4, 10mM) at 37 °C and stirred at 5 × g in order to
simulate a physiologic environment in vitro. The solutions of free DFO or
HA-DFO conjugates were transferred into a dialysis bag (SnakeSkinTM,
MWC0: 10 kDa) (Thermo Scientific Inc., Rockford, IL). Release medium was
replaced with fresh PBS every 4 h to maintain the sink condition. A 60 µL
solution was sampled and mixed with 3mM FeCl (1:1 v/v) at predetermined
intervals. DFO retention was quantified spectrophotometrically. Briefly,
3mM of iron (III) chloride (FeCl3) was incubated with a series of standard
solutions of DFO (0.05–0.5mg/ml), 1 mg/ml HA (215 kDa)-DFO or HA
(752 kDa)-DFO at ambient temperature for 16 h, followed by recording the
absorption at 430 nm (DFO-Iron III chelate complex, ferrioxamine, maximum
absorption), using a microplate reader (SpectraMax Gemini; Molecular
Devices, Sunnyvale, CA).
Cellular radiation protocol
Human Umbilical Vein Endothelial Cells (HUVECs) were obtained from Cell
Applications, Inc. (San Diego, CA). Cells were grown in Cell Applications’
proprietary Endothelial Cell Growth Medium. All cells were utilized at
passage two through four.
HUVECs near confluence were radiated using a Philips RT250
orthovoltage unit (250 kV X-rays, 15mA; Kimtron Medical, Woodbury,
CT), which delivers ionizing radiation through a filtered system. The cells
were exposed to a dose of 5 Gy of radiation in a single fraction according
to previously established protocols proven to successfully impair the
growth and development of cellular cultures.
Tubule formation assay
Matrigel (BD Biosciences, Franklin Lakes, NJ) was thawed and placed in
eight-well chamber slides at 37 °C for 30min to allow for solidification.
Then, control, radiated, or DFO-radiated HUVEC cells (48,000 cells per well)
were plated on Matrigel with 200 µL of 25% HUVEC proprietary media and
A. Donneys et al.
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75% RMPI 1640 media. Cells were then incubated at 37 °C under 23%
oxygen for 4 h. Variable formulations and doses of DFO were administered
as follows: 50 µM DFO, 50 µM HA-DFO, 100 µM HA-DFO. All DFO was
administered at the time of incubation. Cultures were recorded in real time
with live cell imaging and photographed every hour for the duration of the
experiment. Tubule formation was defined as a structure exhibiting a
length four times its width and was analyzed in 10 random fields per well
using an inverted Leica DMIL light microscope (Leica Microsystems,
Wetzlar, Germany) at 100x magnification. Experiments were performed
with a sample size of n= 6, and all data was quantified by three blinded,
independent reviewers.
In vivo study design and animal use
All animal experimentation was conducted in accordance with the
guidelines published in the Guide for the Care and Use of Laboratory
Animals: Eighth Edition.45 Protocols were approved by the University of
Michigan’s Committee for the Utilization and Care of Animals (UCUCA) prior
to implementation. Twelve-week-old male Sprague Dawley rats (n= 46)
weighing approximately 400 g were acclimated for 7 days in light and
temperature-controlled facilities and given food and water ad libitum. Rats
were divided into four groups: Fx (control fracture, n= 5), XFx (irradiated
fracture, n= 15), iDFO (irradiated fracture+ injected deferoxamine, n= 15)
and HA-DFO (irradiated fracture+ hyaluronic acid-deferoxamine implanted
at the time of surgery, n= 11). On day seven, rats underwent fractionated
radiotherapy over a 5 day-period followed by a recuperation period of
14 days prior to surgery. During recovery, animals were acclimated to a soft
chow high-calorie diet (Hills-Columbus Serum; Columbus, Ohio) to ensure
adequate food intake and nutrition in the post-radiation and post-operative
periods. Subsequently, animals underwent osteotomy, DFO injection/
implantation and a 40-day consolidation period as outlined prior to
dissection, bony union analysis, µCT imaging and biomechanical testing. All
46 animals completed the study, however, two animals in the XFx group
had severely comminuted mandibles which precluded subsequent imaging
and biomechanical testing. They were non-unions and thus still considered
in the bony union analysis. Additionally, we powered the experiment based
on expected magnitude of effect of the variables in question given our
previous experience working with this radiated fracture model, so that the
groups were not equal at the start of the experiment, as reported. Each
measurement was taken from each distinct sample.
Animal radiation delivery protocol
All radiation procedures were conducted in the Irradiation Core at the
University of Michigan Cancer Center. After transient induction of
anesthesia with an oxygen/isoflurane mixture, left hemi-mandibles were
radiated using the Philips RT250 orthovoltage unit. Our selected region of
interest (ROI) spans a 2 mm distance posterior to the third molar and
correlates to the future site of surgically created osteotomy. Lead shielding
is provided to ensure localized delivery and protection of surrounding
tissues. A previously described Human Equivalent Dose of Radiation
(HEDR) developed with the guidance of the department of radiation
oncology at the University of Michigan was utilized.46–48 Briefly, a
fractionated dose of 7 Gy per day was administered over 5 days for a
total of 35 Gy. This is comparable to 70 Gy in human mandibular high-dose
radiotherapy. This dose was designed to predictably replicate pathologies
analogous to those observed in the setting of clinically advanced
mandibular osteoradionecrosis, while taking the diminutive size of the
mandible and surrounding tissues into consideration.
DFO administration
The dose and delivery method of iDFO used in these protocols was derived
from an extensive literature search regarding its use in long bone mouse
models and the subsequent advancement of our experimentation with this
drug over recent years.22–29 We have modified the reported dose to
accommodate the larger volume of the rat mandible in our animal model.
DFO (200 µM in 300 µL NS) was given as a local injection directly into the
fracture site every other day starting on post-operative day 4 and
continuing through post-operative day 12. This time frame was chosen to
correlate with the reasonable time for initiation of angiogenesis in a
murine fracture model.8–10 HA-DFO was implanted at the osteotomy site
along the severed bone edges at the time of surgery. The dose of DFO
loaded on the HA scaffold for delivery was calculated at 1000 µM which is
equivalent to the 5 injections of DFO (200 µM each injection) given in our
standard localized injection method.
Peri-operative care
Gentamycin (30mg/kg SQ) was given prophylactically before surgery and
twice post-operatively. To ensure adequate analgesia, hydration and
anesthesia, rats were given buprenorphine (0.15 mg/kg SQ) along with
Lactated Ringers Solution (25 cc/kg SQ), and then anesthetized using an
inhalational isoflurane/oxygen mixture throughout the surgical procedure.
Post-operatively, animals were placed on warming blankets and monitored
for heart and respiratory rates. Post-operative analgesia with buprenor-
phine was continued twice daily until POD 4, and as needed thereafter.
Weight gain, porphyrin staining, food and fluid intake were assessed to
determine the need for continued analgesia.
Osteotomy and fixator placement
After standard preparation and draping a 2 cm midline incision was placed
ventrally from the anterior submentum to the neck crease. After drilling a
1.1 mm hole a 1.5” #0–80 stainless steel rod was threaded horizontally
across the anterior mandible and both ends brought externally through
the skin, creating the anterior portion of our modified external fixator
device. Bilateral holes were then drilled 2 mm anterior and superior to the
mandibular angle, a #0–80 threaded pin was secured through a washer
and brought externally through the skin for the posterior fixator
placement. After stabilization of the fixator, a vertical osteotomy was
created using a10mm micro reciprocating blade (Stryker) ~2 mm anterior
to the posterior washer on the left hemi-mandible, extending from the
inferior margin of the mandible superiorly to the sigmoid notch along the
anterior aspect of the coronoid process. After reduction of the osteotomy
edges, hemostasis was verified, and incisions were closed in layers. Four
hours after osteotomy, the fixator device was set to a 2mm fixed distance
for the length of the experiment as previously described.49
Micro-CT imaging
Micro-CT (GE Healthcare Biosciences) images were obtained using 80 kVp,
80mA and 1100ms exposure at a resolution of 45-micron voxel size for
bone analysis. The individual scans were reconstructed and reoriented in a
three-dimensional x, y and z plane, then several rotations and cropping of
non-bone space were undertaken for uniformity. The region of interest was
selected correlating to the region of fracture healing, 2 mm directly behind
the third molar. Using Microview software the ROI was then highlighted
and analyzed for bone mineral density (BMD), tissue mineral density (TMD)
and bone volume fraction (BVF).
Biomechanical testing
Pins were inserted perpendicularly through the hemi-mandibles at both
existing anterior and posterior pin-site holes. The posterior and anterior
aspects of the mandible were potted using a Cerrobend Bismuth alloy. The
mandible was positioned inside the pot with the inferior edge of the
mandible perpendicular to the top edge of the pot. Using a servohydraulic-
testing machine (858 Mini Bionics II; MTS Systems), potted hemi-mandibles
were loaded to failure using tension at a constant displacement rate of
0.5 mm/s. Displacement was monitored with an external linear variable
differential transducer (LVDT; Howard A. Schaevitz Technologies). The load
and displacement data were acquired using the TestStar IIs system (version
2.4; MTS) at a sampling frequency of 200 Hz. A custom LabVIEW script was
used to analyze the raw force-displacement data. Load-Displacement
curves were analyzed for stiffness (S), and failure load (FL).
Bony union analysis
En-bloc dissection of mandibles allowed for assessment of bony union.
This was clinically defined as the absence of movement across the
regenerate site on manual manipulation of the regenerate gap after
removal of the fixator device. Union status was subsequently verified with
micro-computed tomography (μCT) imaging where possible.
Statistical analysis
All statistical analysis was conducted using SPSS software (v24; IBM).
Outcome metrics were compared utilizing a one-way analysis of variance
and reported as means ± standard deviation with p < 0.05 considered
statistically significant. Points of significance are symbolized graphically (*).
No covariates, assumptions or corrections were employed. A post hoc
Tukey test was used for multiple comparisons.
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
All supporting data in the published article generated during the study can be
obtained by contacting the corresponding author.
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